Literature DB >> 17097610

Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells.

Atsushi Suetsugu1, Masahito Nagaki, Hitomi Aoki, Tsutomu Motohashi, Takahiro Kunisada, Hisataka Moriwaki.   

Abstract

The CD133 antigen, identified as a hematopoietic stem cell marker, appears in various human embryonic epithelia including the neural tube, gut, and kidney. We herein investigated whether CD133(+) cells isolated from human hepatocellular carcinoma cell lines possess cancer stem/progenitor cell-like properties. Among the three cell lines studied, the CD133 antigen was found to be expressed only on the surface of Huh-7 cells. CD133(+) cells from Huh-7 performed a higher in vitro proliferative potential and lower mRNA expressions of mature hepatocyte markers, glutamine synthetase and cytochrome P450 3A4, than CD133(-) population of Huh-7 cells. When either CD133(+) or CD133(-) cells were subcutaneously injected into SCID mice, CD133(+) cells formed tumors, whereas CD133(-) cells induced either a very small number of tumors or none at all. Taken together, the identification of CD133(+) cells could thus be a potentially powerful tool to investigate the tumorigenic process in the hepatoma system and to also develop effective therapies targeted against hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17097610     DOI: 10.1016/j.bbrc.2006.10.128

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  210 in total

1.  Evidence for label-retaining tumour-initiating cells in human glioblastoma.

Authors:  Loic P Deleyrolle; Angus Harding; Kathleen Cato; Florian A Siebzehnrubl; Maryam Rahman; Hassan Azari; Sarah Olson; Brian Gabrielli; Geoffrey Osborne; Angelo Vescovi; Brent A Reynolds
Journal:  Brain       Date:  2011-04-22       Impact factor: 13.501

2.  Emerging strategies for the identification and targeting of cancer stem cells.

Authors:  Jun Dou; Ning Gu
Journal:  Tumour Biol       Date:  2010-03-25

3.  CD133+ CD44+ subgroups may be human small intestinal stem cells.

Authors:  Neng-Yi Hou; Kun Yang; Tie Chen; Xin-Zu Chen; Bo Zhang; Xian-Ming Mo; Jian-Kun Hu
Journal:  Mol Biol Rep       Date:  2010-06-06       Impact factor: 2.316

Review 4.  Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications.

Authors:  J U Marquardt; V M Factor; S S Thorgeirsson
Journal:  J Hepatol       Date:  2010-05-31       Impact factor: 25.083

Review 5.  Beta-catenin signaling, liver regeneration and hepatocellular cancer: sorting the good from the bad.

Authors:  Kari Nichole Nejak-Bowen; Satdarshan P S Monga
Journal:  Semin Cancer Biol       Date:  2010-12-21       Impact factor: 15.707

6.  Transcriptional profiling of dividing tumor cells detects intratumor heterogeneity linked to cell proliferation in a brain tumor model.

Authors:  Berwini B Endaya; Paula Y P Lam; Adrian C B Meedeniya; Jiri Neuzil
Journal:  Mol Oncol       Date:  2015-09-10       Impact factor: 6.603

7.  8-bromo-7-methoxychrysin inhibits properties of liver cancer stem cells via downregulation of β-catenin.

Authors:  Mei-Fang Quan; Li-Hong Xiao; Zhi-Hong Liu; Hui Guo; Kai-Qun Ren; Fei Liu; Jian-Guo Cao; Xi-Yun Deng
Journal:  World J Gastroenterol       Date:  2013       Impact factor: 5.742

Review 8.  CD133: to be or not to be, is this the real question?

Authors:  Elena Irollo; Giuseppe Pirozzi
Journal:  Am J Transl Res       Date:  2013-09-25       Impact factor: 4.060

Review 9.  In search of liver cancer stem cells.

Authors:  Stephanie Ma; Kwok Wah Chan; Xin-Yuan Guan
Journal:  Stem Cell Rev       Date:  2008-07-29       Impact factor: 5.739

Review 10.  Stem cells, a two-edged sword: risks and potentials of regenerative medicine.

Authors:  Anna-Chiara Piscaglia
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.